NCT00644501 - Long-Term Treatment Effect of DiaPep277 in Type 1 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

May 31, 2013

Study Completion Date

June 30, 2013

Conditions

Type 1 Diabetes

Interventions

DRUG

DiaPep277

1.0mg dose, injected subcutaneously at baseline and every 3 months thereafter (at 0, 3, 6, 9, 12, 15, 18, 21 months)for a total of 8 administrations.

Trial Locations (3)

Schneider Children's Medical Centre, Petah Tikva

Wolfson Medical Centre, Holon

Diabetic Unit, Hadassah Medical Center, Jerusalem